Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles

A Publisher Correction to this article was published on 22 January 2019

This article has been updated


Deposition of complement factors (opsonization) on nanoparticles may promote clearance from the blood by macrophages and trigger proinflammatory responses, but the mechanisms regulating the efficiency of complement activation are poorly understood. We previously demonstrated that opsonization of superparamagnetic iron oxide (SPIO) nanoworms with the third complement protein (C3) was dependent on the biomolecule corona of the nanoparticles. Here we show that natural antibodies play a critical role in C3 opsonization of SPIO nanoworms and a range of clinically approved nanopharmaceuticals. The dependency of C3 opsonization on immunoglobulin binding is almost universal and is observed regardless of the complement activation pathway. Only a few surface-bound immunoglobulin molecules are needed to trigger complement activation and opsonization. Although the total amount of plasma proteins adsorbed on nanoparticles does not determine C3 deposition efficiency, the biomolecule corona per se enhances immunoglobulin binding to all nanoparticle types. We therefore show that natural antibodies represent a link between biomolecule corona and C3 opsonization, and may determine individual complement responses to nanomedicines.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Role of immunoglobulins in efficiency of C3 deposition on SPIO nanoworms.
Fig. 2: Role of immunoglobulins in efficiency of C3 deposition on clinically approved SPIO Feraheme.
Fig. 3: Role of immunoglobulins in efficiency of C3 deposition on clinically approved liposomes.
Fig. 4: Association between immunoglobulin and C3 in the protein corona.
Fig. 5: Role of biomolecule corona in C3 and IgG deposition.
Fig. 6: Proposed scheme of the role of biomolecule corona and immunoglobulin in activation of the alternative pathway.

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD011781. The raw data that support the graphs in Figs. 1c,d,e,g,h,i; 2c,d,e,f; 3c,d,e,f,i,j,k,l; and 5d are available in extended Supplementary Information. Any additional data and data analysis scripts for R are available from L.S. upon request.

Change history

  • 22 January 2019

    In the version of this Article originally published, a technical error led to Fig. 1a containing ‘!!!!!!!!’ above the scale bar. This has now been corrected in all versions of the Article.


  1. 1.

    D’Mello, S. R. et al. The evolving landscape of drug products containing nanomaterials in the United States. Nat. Nanotech. 12, 523–529 (2017).

    Google Scholar 

  2. 2.

    Boraschi, D. et al. Nanoparticles and innate immunity: new perspectives on host defence. Semin. Immunol. 34, 33–51 (2017).

    CAS  Google Scholar 

  3. 3.

    Monopoli, M. P. et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133, 2525–2534 (2011).

    CAS  Google Scholar 

  4. 4.

    Cedervall, T. et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104, 2050–2055 (2007).

    CAS  Google Scholar 

  5. 5.

    Karmali, P. P. & Simberg, D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert. Opin. Drug. Deliv. 8, 343–357 (2011).

    CAS  Google Scholar 

  6. 6.

    Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotech. 8, 137–143 (2013).

    CAS  Google Scholar 

  7. 7.

    Mortimer, G. M. et al. Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano 8, 3357–3366 (2014).

    CAS  Google Scholar 

  8. 8.

    Shannahan, J. H. et al. Formation of a protein corona on silver nanoparticles mediates cellular toxicity via scavenger receptors. Toxicol. Sci. 143, 136–146 (2015).

    CAS  Google Scholar 

  9. 9.

    Deng, Z. J. et al. Nanoparticle-induced unfolding of fibrinogen promotes mac-1 receptor activation and inflammation. Nat. Nanotech. 6, 39–44 (2011).

    CAS  Google Scholar 

  10. 10.

    Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785–797 (2010).

    CAS  Google Scholar 

  11. 11.

    Wibroe, P. P. et al. Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nat. Nanotech. 12, 589–594 (2017).

    CAS  Google Scholar 

  12. 12.

    Anchordoquy, T. J. & Simberg, D. Watching the gorilla and questioning delivery dogma. J. Control. Release 262, 87–90 (2017).

    CAS  Google Scholar 

  13. 13.

    Moghimi, S. M. Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. Drug Discov. Today 23, 1034–1042 (2018).

    CAS  Google Scholar 

  14. 14.

    Chanan-Khan, A. et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14, 1430–1437 (2003).

    CAS  Google Scholar 

  15. 15.

    Chen, F. et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat. Nanotech. 12, 387–393 (2017).

    CAS  Google Scholar 

  16. 16.

    Nahrendorf, M. et al. Hybrid PET-optical imaging using targeted probes. Proc. Natl Acad. Sci. USA 107, 7910–7915 (2010).

    Google Scholar 

  17. 17.

    Gazeau, F., Levy, M. & Wilhelm, C. Optimizing magnetic nanoparticle design for nanothermotherapy. Nanomedicine (Lond.) 3, 831–844 (2008).

    CAS  Google Scholar 

  18. 18.

    Benasutti, H. et al. Variability of complement response toward preclinical and clinical nanocarriers in the general population. Bioconjug. Chem. 28, 2747–2755 (2017).

    CAS  Google Scholar 

  19. 19.

    Schenkein, H. A. & Ruddy, S. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway. J. Immunol. 126, 11–15 (1981).

    CAS  Google Scholar 

  20. 20.

    Schenkein, H. A. & Ruddy, S. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human igg with specificity for zymosan enhances alternative pathway activation by zymosan. J. Immunol. 126, 7–10 (1981).

    CAS  Google Scholar 

  21. 21.

    Russell, M. W. & Mansa, B. Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound, IgA. Scand. J. Immunol. 30, 175–183 (1989).

    CAS  Google Scholar 

  22. 22.

    Andersson, J., Ekdahl, K. N., Lambris, J. D. & Nilsson, B. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials. 26, 1477–1485 (2005).

    CAS  Google Scholar 

  23. 23.

    Wang, G. et al. High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. ACS Nano 8, 12437–12449 (2014).

    CAS  Google Scholar 

  24. 24.

    Wang, G. et al. In vitro and in vivo differences in murine third complement component (C3) opsonization and macrophage/leukocyte responses to antibody-functionalized iron oxide nanoworms. Front. Immunol. 8, 151 (2017).

    Google Scholar 

  25. 25.

    Duncan, A. R. & Winter, G. The binding site for C1q on IgG. Nature 332, 738–740 (1988).

    CAS  Google Scholar 

  26. 26.

    Banda, N. K. et al. Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis Rheum. 58, 3081–3089 (2008).

    Google Scholar 

  27. 27.

    Malhotra, R. et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1, 237–243 (1995).

    CAS  Google Scholar 

  28. 28.

    Wang, G. et al. Activation of human complement system by dextran-coated iron oxide nanoparticles is not affected by dextran/Fe ratio, hydroxyl modifications, and crosslinking. Front. Immunol. 7, 418 (2016).

    Google Scholar 

  29. 29.

    Quach, Q. H. & Kah, J. C. Non-specific adsorption of complement proteins affects complement activation pathways of gold nanomaterials. Nanotoxicology 11, 382–394 (2017).

    CAS  Google Scholar 

  30. 30.

    Harris, C. L., Heurich, M., Rodriguez de Cordoba, S. & Morgan, B. P. The complotype: dictating risk for inflammation and infection. Trends Immunol. 33, 513–521 (2012).

    CAS  Google Scholar 

  31. 31.

    Macdougall, I. C. Iron supplementation in nephrology and oncology: what do we have in common? Oncologist 16(Suppl. 3), 25–34 (2011).

    Google Scholar 

  32. 32.

    Gabizon, A. & Martin, F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54(Suppl.4), 15–21 (1997).

    CAS  Google Scholar 

  33. 33.

    Hamad, I., Hunter, A. C., Szebeni, J. & Moghimi, S. M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46, 225–232 (2008).

    CAS  Google Scholar 

  34. 34.

    Kang, M. H. et al. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin. Cancer Res. 21, 1139–1150 (2015).

    CAS  Google Scholar 

  35. 35.

    Ramadass, M., Ghebrehiwet, B., Smith, R. J. & Kew, R. R. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies. J. Immunol. 192, 1220–1230 (2014).

    CAS  Google Scholar 

  36. 36.

    Gadd, K. J. & Reid, K. B. The binding of complement component C3 to antibody–antigen aggregates after activation of the alternative pathway in human serum. Biochem. J. 195, 471–480 (1981).

    CAS  Google Scholar 

  37. 37.

    Pauly, D. et al. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One 9, e96371 (2014).

    Google Scholar 

  38. 38.

    Sakulkhu, U. et al. Protein corona composition of superparamagnetic iron oxide nanoparticles with various physico-chemical properties and coatings. Sci. Rep. 4, 5020 (2014).

    CAS  Google Scholar 

  39. 39.

    Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotech. 8, 772–781 (2013).

    CAS  Google Scholar 

  40. 40.

    Walkey, C. D. et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8, 2439–2455 (2014).

    CAS  Google Scholar 

  41. 41.

    Holodick, N. E., Rodriguez-Zhurbenko, N. & Hernandez, A. M. Defining natural antibodies. Front. Immunol. 8, 872 (2017).

    Google Scholar 

  42. 42.

    Moghimi, S. M. & Simberg, D. Complement activation turnover on surfaces of nanoparticles. Nano Today 15, 8–10 (2017).

    CAS  Google Scholar 

  43. 43.

    Sulica, A. et al. Effect of protein A of Staphylococcus aureus on the binding of monomeric and polymeric IgG to Fc receptor-bearing cells. Immunology 38, 173–179 (1979).

    CAS  Google Scholar 

  44. 44.

    Le, Y., Toyofuku, W. M. & Scott, M. D. Immunogenicity of murine mPEG-red blood cells and the risk of anti-PEG antibodies in human blood donors. Exp. Hematol. 47, 36–47 e32 (2017).

    CAS  Google Scholar 

  45. 45.

    Jones, J. V., James, H., Tan, M. H. & Mansour, M. Antiphospholipid antibodies require beta 2-glycoprotein I (apolipoprotein H) as cofactor. J. Rheumatol. 19, 1397–1402 (1992).

    CAS  Google Scholar 

  46. 46.

    Laky, M., Sjoquist, J., Moraru, I. & Ghetie, V. Mutual inhibition of the binding of Clq and protein A to rabbit IgG immune complexes. Mol. Immunol. 22, 1297–1302 (1985).

    CAS  Google Scholar 

  47. 47.

    Zhang, L. et al. A second IgG-binding protein in Staphylococcus aureus. Microbiology 144, 985–991 (1998).

    CAS  Google Scholar 

  48. 48.

    Fries, L. F., Gaither, T. A., Hammer, C. H. & Frank, M. M. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J. Exp. Med. 160, 1640–1655 (1984).

    CAS  Google Scholar 

  49. 49.

    Venkatesh, Y. P., Minich, T. M., Law, S. K. & Levine, R. P. Natural release of covalently bound C3b from cell surfaces and the study of this phenomenon in the fluid-phase system. J. Immunol. 132, 1435–1439 (1984).

    CAS  Google Scholar 

  50. 50.

    Molday, R. S. & MacKenzie, D. Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J. Immunol. Methods 52, 353–367 (1982).

    CAS  Google Scholar 

  51. 51.

    Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 6, 359–362 (2009).

    CAS  Google Scholar 

Download references


The study was funded by the National Institutes of Health grants EB022040, CA194058, CA174560 to D.S. and Diagnologix, LLC (San Diego, CA) to D.S. F.C. was supported by the International Postdoctoral Exchange Fellowship Program (2013) from China Postdoctoral Council. S.M.M. acknowledges support by International Science and Technology Cooperation of Guangdong Province (reference 2015A050502002), and Guangzhou City (reference 2016201604030050) with RiboBio Co., Ltd., China. The authors thank N. K. Banda and V. M. Holers for their suggestions during this work.

Author information




V.P.V., F.C., H.B., E.V.G., G.B.G. and G.W. performed the experiments. R.S., L.S., S.M.M. and D.S. analysed the data. S.M.M. and D.S. conceived the experiments and wrote the manuscript.

Corresponding author

Correspondence to Dmitri Simberg.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vu, V.P., Gifford, G.B., Chen, F. et al. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Nat. Nanotechnol. 14, 260–268 (2019).

Download citation

Further reading


Quick links

Find nanotechnology articles, nanomaterial data and patents all in one place. Visit Nano by Nature Research